Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury by Ohnishi, Masatoshi et al.
熊本大学学術リポジトリ
Kumamoto University Repository System
Title Involvement of thrombin and mitogen-activated
protein kinase pathways in hemorrhagic brain injury
Author(s)Ohnishi, Masatoshi; Katsuki, Hiroshi; Fujimoto,
Shinji; Takagi, Mikako; Kume, Toshiaki; Akaike,
Akinori
CitationExperimental Neurology, 206(1): 43-52
Issue date2007-07
Type Journal Article
URL http://hdl.handle.net/2298/10013
Right ? 2007 Elsevier Inc. All rights reserved.
  
 
Involvement of thrombin and mitogen-activated protein kinase pathways in 
hemorrhagic brain injury 
 
Masatoshi Ohnishi, Hiroshi Katsuki, Shinji Fujimoto, Mikako Takagi, Toshiaki Kume, 
Akinori Akaike 
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto 
University, 46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan. 
 
 
 
 
Address correspondence to Akinori Akaike, Ph.D. 
Department of Pharmacology, 
Graduate School of Pharmaceutical Sciences, Kyoto University 
46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan. 
Phone: +81-75-753-4550  FAX: +81-75-753-4579 
E-mail: aakaike@pharm.kyoto-u.ac.jp 
 
 1
Abstract 
Thrombin is thought to play an important role in brain damage associated with intracerebral 
hemorrhage (ICH).  We previously showed that activation of mitogen-activated protein 
(MAP) kinases and recruitment of microglia are crucial for thrombin-induced shrinkage of the 
striatal tissue in vitro and thrombin-induced striatal damage in vivo.  Here we investigated 
whether the same mechanisms are involved in ICH-induced brain injury.  A substantial loss 
of neurons was observed in the center and the peripheral region of hematoma at 3 days after 
ICH induced by intrastriatal injection of collagenase in adult rats.  Intracerebroventricular 
injection of argatroban or cycloheximide, both of which prevent thrombin cytotoxicity in vitro, 
exhibited a significant neuroprotective effect against ICH-induced injury.  ICH-induced 
neuron loss was also prevented by a MAP kinase kinase inhibitor (PD98059) and a c-Jun 
N-terminal kinase inhibitor (SP600125).  These drugs had no effect on hematoma size or 
ICH-induced brain edema.  Activation of extracelluar signal-regulated kinase in response to 
ICH was observed in both neurons and microglia.  Despite their neuroprotective effects, 
MAP kinase inhibitors did not decrease the number of terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells appearing after ICH.  
Identification of cell types revealed that TUNEL staining occurred prominently in neurons but 
not in microglia, whereas inhibition of MAP kinases resulted in appearance of TUNEL 
staining in microglia.  These results suggest that thrombin and the activation of MAP kinases 
are involved in ICH-induced neuronal injury, and that neuroprotective effects of MAP kinases 
are in part mediated by arrestment of microglial activities. 
 
Keywords: intracerebral hemorrhage; microglia; thrombin; mitogen-activated protein kinase; 
apoptosis  
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Introduction 
Intracerebral hemorrhage (ICH) is characterized by breakdown of blood vessels within the 
brain parenchyma, which triggers a substantial loss of neurons that frequently leads to poor 
prognosis (Fayad and Awad, 1998).  Fundamental therapeutic strategies for ICH, particularly 
those aimed at neuroprotection, have yet to be established. 
Blood-intrinsic factors are primarily involved in neuronal damage occurring after ICH.  
Several lines of evidence have indicated that thrombin, a blood coagulation factor, plays an 
important role in the pathogenesis of ICH, although other factors such as hemoglobin may 
also participate in neuron loss (Xi et al., 2006).  At low concentrations, thrombin may 
provide cytoprotective effects on neurons and astrocytes against oxidative stress and ischemic 
injury (Donovan and Cunningham, 1998; Striggow et al., 2000; Vaughan et al., 1995).  By 
contrast, uncontrolled thrombin activity after ICH may be involved in neuronal cell death as 
well as brain edema.  Indeed, a thrombin inhibitor argatroban has been shown to suppress the 
progression of pathogenic events following ICH (Kitaoka et al., 2002; Nagatsuna et al., 2005).  
Thrombin, with its serine protease activity, stimulates G protein-coupled receptors designated 
as proteinase-activated receptors (PARs), which are widely distributed in the central nervous 
system (Flynn et al., 2004; Noobakhsh et al., 2003).  Stimulation of PARs activates various 
intracellular signaling enzymes, including members of mitogen-activated protein (MAP) 
kinase family such as extracelluar signal-regulated kinase (ERK), p38 mitogen-activated 
protein kinase (p38 MAPK) and c-Jun N-terminal kinase (JNK) (Marinissen et al., 2003; Suo 
et al., 2003; Wang et al., 2002). 
Recently, we investigated the mechanisms of thrombin-induced neuronal injury in vitro 
(Fujimoto et al., 2006) and in vivo (Fujimoto et al., 2007).  In organotypic cortico-striatal 
slice cultures, thrombin induced shrinkage of the striatal tissue, which was prevented by 
inhibition of ERK, p38 MAPK or JNK.  In addition, depletion of microglia protected striatal 
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tissue from thrombin-induced injury (Fujimoto et al., 2006).  Activation of MAP kinase 
pathways and recruitment of microglia have also been demonstrated in neuronal injury 
induced by intrastriatal injection of thrombin in adult rats (Fujimoto et al., 2007). 
Given that thrombin is involved in ICH-associated neuronal injury, one can assume that 
signaling mechanisms similar to those recruited by thrombin insults plays an important role in 
the pathogenesis of ICH.  However, effects of MAP kinase inhibition on ICH-induced injury 
have not been reported.  Therefore, in the present study we addressed this issue using an 
established animal model of ICH, i.e., rats that received intrastriatal microinjection of 
collagenase (Terai et al., 2003; Xue et al., 2003). 
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Materials and methods 
Induction of intracerebral hemorrhage and drug treatment 
Experiments were conducted in accordance with the ethical guidelines of Kyoto University 
animal experimentation committee, and with the Guidelines of the United States National 
Institutes of Health regarding the care and use of animals for experimental procedures.  
Drugs and chemicals were obtained from Nacalai Tesque (Kyoto, Japan), unless otherwise 
indicated.  
We used 208 male Sprague-Dawley rats (Nihon SLC, Shizuoka, Japan) weighing 220 to 280 
g.  Animals were maintained at constant ambient temperature (22 ± 1 °C) under a 12 h light 
and dark cycle.  After intraperitoneal injection of pentobarbital (50 mg/kg, 
Dainippon-Sumitomo, Osaka, Japan), rats were placed in a stereotaxic frame (Narishige, 
Tokyo, Japan).  Each rat was implanted with stainless steel guide cannulas (o.d. 0.7 mm) 
above the right striatum (3 mm lateral to midline, 0.2 mm anterior to coronal suture of the 
bregma) and above the lateral ventricle (1.5 mm lateral to midline, 0.8 mm posterior to 
coronal suture of the bregma).  Guide cannulas were held firmly in place by dental acrylic 
cement (Nissin Dental Products Inc., Kyoto, Japan).  The 27-gauge injection cannula, whose 
tip was inserted 6.0 mm below the surface of the skull, was introduced through a guide 
cannula into the right striatum, and then ICH was induced by injection of 0.25 U collagenase 
type IV (Sigma, St. Louis, MO, USA) in 5 μl saline, at a constant rate of 0.50 μl/min with a 
microinfusion pump.  Argatroban (2.5 μg, Sawai Pharmaceuticals, Osaka, Japan) and 
cycloheximide (10 nmol, Wako Pure Chemicals, Osaka, Japan) were injected into the 
ipsilateral ventricle 1 h before induction of ICH, and then once daily afterwards for 3 days.   
MAP kinase inhibitors (PD98059 (Calbiochem, San Diego, CA, USA), SB203580 
(Calbiochem) and SP600125 (Tocris Cookson, Bristol, UK), 5 nmol respectively) with 33% 
DMSO as vehicle were injected into the contralateral ventricle at the same time course as that 
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for argatroban and cycloheximide.  Each drug solution in a volume of 5 μl/rats was infused 
at a constant rate of 10.0 μl/min.  In several sets of experiments where histological and 
biochemical determinations were done at less than 48 h after ICH, rats received injection of 
drugs only at 1 h before collagenase injection.  After injection, the injection cannula was left 
in place for 5 min and then removed slowly.  The scalp incision was sutured, and rats were 
placed in a cage with free access to food and water. 
 
Immunohistochemistry and assessment of hematoma size 
Three days or 8 h after ICH, rats were anesthetized again and perfused transcardially with 60 
ml cold phosphate-buffered saline (PBS) followed by 60 ml of 4% paraformaldehyde (PFA).  
Brains were isolated and fixed in 4% PFA for 2 h and then were soaked in 15% sucrose 
overnight at 4 °C.  After freezing, they were cut into sections of 16 μm thicknesses with a 
Cryostat (Leica Microsystems, Germany) and were pasted to silanized slide glasses.  
Activation of NeuN antigen was achieved by soaking of specimens in 10 mM citric acid (pH 
6.0) for 15 min at 121 °C with autoclave.  After rinse with PBS, specimens were treated with 
0.5% Triton X-100 in PBS containing 1.5% horse or goat serum for 1 h at room temperature, 
then incubated with primary antibodies overnight at 4 °C.  Primary antibodies were mouse 
anti-NeuN (1:200, Chemicon International, Temecula, CA, USA), mouse anti-OX-42 (1:300, 
Dainippon Pharmaceutical, Osaka, Japan) and rabbit anti-phospho-p44/42 MAP kinase 
(T202/204) (1:250, Cell Signaling Technology, Beverly, MA, USA).  After rinse with PBS, 
specimens were incubated with corresponding secondary antibodies for 1 h at room 
temperature.  Alexa Fluor 488-labeled goat anti-rabbit IgG (1:200, Molecular Probes, 
Eugene, OR, USA), Alexa Fluor 568-labeled goat anti-mouse IgG (1:200, Molecular Probes) 
and biotinylated anti-mouse IgG (1:200, Vector Laboratories, Burlingame, CA, USA) were 
used as secondary antibodies.  After incubation with the biotinylated secondary antibody, 
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specimens were treated with avidin-biotinylated horseradish peroxidase complex (Vectastain 
Elite ABC kit, Vector Laboratories) and then peroxidase was visualized with 
diaminobendizine and H2O2.  Bright-field images were captured through a monochrome 
chilled CCD camera (C5985; Hamamatsu Photonics, Hamamatsu, Japan) and stored as image 
files.  The number of NeuN- or OX-42-positive cells per 230 × 320 μm2 was counted at the 
center and the peripheral region of hematoma as shown in Fig. 1.  The area with low 
NeuN-immunoreactivity in a coronal section containing a track of cannula for collagenase 
injection was taken as hematoma area, which was quantified with Scion image.  
Fluorescence signals were observed with a laser-scanning confocal microscopic system 
(MRC1024, Biorad, Hercules, CA, USA). 
 
Measurement of brain water content 
Three days after ICH, rats were decapitated under deep anesthesia.  Two coronal brain 
slices (A and B) with 3 mm thickness were cut at 3 mm from the frontal pole.  Slice A 
contained the bleeding site by collagenase injection, and slice B was adjacent and caudal to 
slice A.  Slices were divided into the ipsilateral and the contralateral side and the wet weight 
of these samples were obtained.  Samples were then dried in a gravity oven at 75 °C for 12 h 
to give the dry weight.  The water content was calculated by the following formula: (wet 
weight − dry weight) / wet weight × 100 (%). 
 
Western blot analysis 
Rats were decapitated under deep anesthesia at 4, 8, 24 and 48 h following ICH.  Rats of 
control group were decapitated at 4 h after intrastriatal injection of saline.  The striatal tissue 
adjacent to the hematoma were homogenized in ice-cold lysis buffer consisting of 20 mM 
Tris-HCl (pH 7.0), 25 mM β-glycerophosphate (Sigma), 2 mM EGTA･2Na, 1% Triton X-100, 
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1 mM vanadate, 1% aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride and 2 mM 
dithiothreitol.  Samples were mixed with a sample buffer composed of 124 mM Tris-HCl 
(pH 6.8), 4% sodium dodecyl sulfate (SDS), 10% glycerol, 0.02% bromophenol blue and 4% 
2-mercaptoethanol.  After boiling for 5 min, samples were subjected to 12% 
SDS-polyacrylamide gel electrophoresis for 70 min, followed by transfer to PVDF membrane 
(Millipore) for 70 min.  Membranes were blocked for at least 1 h by 5% nonfat milk at room 
temperature and subsequently incubated overnight with mouse anti-phospho-p44/42 MAP 
kinase (T202/Y204) (1:2000, Cell Signaling Technology) and anti-p-44/42 MAP kinase 
(1:1000, Cell Signaling Technology).  The membranes were rinsed and incubated with 
horseradish peroxidase-conjugated goat anti-mouse IgG (1:10000, Jackson Immunoresearch 
Laboratories) and goat anti-rabbit IgG (1:10000, Jackson Immunoresearch Laboratories).  
After incubation with secondary antibodies, membranes were rinsed and bound antibodies 
were detected with enhanced chemiluminescence kit (Amersham Bioscience, 
Buckinghamshire, UK) according to the manufacturer’s instructions.  The band intensities 
were analyzed with Scion Image. 
 
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) 
TUNEL was carried out with a commercial kit (TAKARA BIO Inc., Shiga, Japan).  One 
day after ICH, rats were decapitated under deep anesthesia, brains were isolated and frozen, 
and coronal brain sections (16 μm) were prepared and mounted onto slides.  Specimens were 
then fixed with 4% PFA for 15 min at room temperature.  Epitope was retrieved by treatment 
with 20 μg/ml proteinase K (Ambion, USA) for 20 min at room temperature.  Intrinsic 
peroxidase was blocked with 3% H2O2 applied for 10 min, and after permeabilization, 
specimens were incubated with constructed labeling reaction solution containing TdT enzyme 
(1:10) for 120 min at 37 °C.  After rinse with PBS, specimens were incubated with 
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anti-FITC HRP conjugate as a primary antibody overnight at 37 °C, and then, with 
biotinylated anti-rabbit IgG (1:200) for 2 h at room temperature.  After rinse with PBS, 
specimens were treated with avidin-biotinylated horseradish peroxidase complex.  
Peroxidase was visualized with diaminobendizine and H2O2, or with Tyramide Signal 
Amplification kit with Alexa Fluor 488 (Molecular Probes).  Specimens with fluorescent 
TUNEL staining were further processed for immunohistochemistry.  Mouse anti-NeuN 
(1:200) and mouse anti-OX-42 (1:300) were used as primary antibodies, and Alexa Fluor 
568-labeled goat anti-mouse IgG (1:200) was used as a secondary antibody. 
 
Statistics 
Data are expressed as means ± SEM.  Statistical significance of difference was evaluated 
with one-way analysis of variance followed by Student-Newman-Keuls’ test, unless otherwise 
indicated.  When the data sets were not suitable for these parametric tests, non-parametric 
Kruskal-Wallis test followed by Dunn’s multiple comparisons test was used.  Probability 
values less than 5% were considered significant. 
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Results 
ICH-induced loss of striatal neurons is prevented by argatroban and cycloheximide 
We injected collagenase into the right striatum of adult rats to evoke ICH.  Brain sections 
were obtained 3 days after collagenase injection and immunostained with an antibody against 
NeuN, a neuronal marker.  Macroscopic observations of immunostained sections revealed 
that the striatal region corresponding to the hematoma area of collagenase-injected rats 
exhibited much lower NeuN-positive signals, compared to the striatum of saline-injected rats 
(Fig. 1A and B).  At higher magnification, a substantial decrease in the number of 
NeuN-positive cells was evident within the hematoma area (Fig. 1D, compared to Fig. 1C). 
Argatroban, a thrombin inhibitor, has been shown to inhibit thrombin-induced injury of 
striatal tissue in organotypic slice culture (Fujimoto et al., 2006).  To clarify the involvement 
of thrombin in ICH-induced injury, we examined the effect of repeated intracerebroventricular 
(i.c.v.) injection of argatroban.  We used argatroban at the highest dose (2.5 μg) contained in 
an injection solution, which was the only formula of this drug commercially available.  
Treatment with 2.5 μg argatroban 1 h before, as well as 1 and 2 days after collagenase 
injection, significantly increased the number of remaining NeuN-positive cells at the 
hematoma center, i.e., around the injection site of collagenase (Fig. 2A-C, E).  The number 
of surviving neurons was also increased in the peripheral region of hematoma by argatroban 
treatment, although the effect did not reach statistical significance (Fig. 2F). 
Our previous study also demonstrated that cycloheximide, a protein synthesis inhibitor, 
prevented thrombin-induced striatal injury in vitro (Fujimoto et al., 2006).  Consistent with 
this observation, treatment with 10 nmol cycloheximide, in the same manner as that with 
argatroban, significantly increased the number of surviving neurons in the hematoma center 
(Fig. 2D, E) and tended to increase the number of surviving neurons in the peripheral region 
of hematoma (Fig. 2F).  A lower dose (1 nmol) of cyloheximide showed no effect (data not 
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shown).  The extent of protection by 2.5 μg argatroban and 10 nmol cycloheximide did not 
differ significantly with each other. 
 
ICH-induced loss of striatal neurons is prevented by MAP kinase inhibitors 
Thrombin triggers activation of multiple members of MAP kinase family, including ERK, 
p38 MAPK and JNK (Flynn et al., 2004; Noobakhsh et al., 2003).  All of these MAP kinases 
participate in thrombin-induced striatal tissue injury in culture (Fujimoto et al., 2006).  
Accordingly, we examined the effects of MAP kinase inhibitors against ICH-induced neuronal 
injury.  We used PD98059 as an ERK kinase inhibitor, SB203580 as a p38 MAPK inhibitor 
and SP600125 as a JNK inhibitor.  DMSO was used at 33% in a vehicle for i.c.v. injection of 
these inhibitors because of their poor solubility.  As compared to saline, 33% DMSO 
produced no effect on the number of neurons (compare Fig. 3 with Fig. 2).  In addition, i.c.v. 
injection of DMSO had no effect on brain water content (Fig. 4) and the number of TUNEL- 
and OX-42-positive cells (data not shown).  Furthermore, we did not observe any abnormal 
behaviors in rats injected with 33% DMSO.  The doses of inhibitors were set to 5 nmol, 
based on the fact that all of these drugs at 100 μM prevented thrombin-induced shrinkage of 
the striatal tissue in vitro (Fujimoto et al., 2006).  Also, poor solubility of these drugs 
hampered their usage at higher doses.  I.c.v. injections of PD98059 1 h before, as well as 1 
and 2 days after collagenase injection, significantly increased the number of surviving 
neurons in the hematoma center and in the peripheral region of hematoma at 3 days after 
collagenase injection (Fig. 3).  SP600125 applied in the same manner significantly increased 
the number of surviving neurons in the peripheral region of hematoma, and tended to increase 
the number of surviving neurons in the hematoma center.  SB203580 also tended to increase 
the number of surviving neurons both in the hematoma center and in the peripheral region of 
hematoma, but the effect did not reach statistical significance.  Overall, the protective effect 
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of PD98059 was most prominent in the sense that this drug was effective both in the center 
and the peripheral region of hematoma, although we did not obtain a statistically significant 
difference among the effects of PD98059, SB203580 and SP600125. 
 
Argatroban, cycloheximide, and MAP kinase inhibitors do not affect hematoma size and brain 
water content 
We next examined the effects of drugs on the size of hematoma, to determine if these drugs 
may affect the amount of bleeding after ICH.  We regarded the striatal region with low NeuN 
immunoreactivity as the area invaded by hematoma, and measured the hematoma size 3 days 
after ICH, in the coronal section containing the track of cannula for collagenase injection.  
The size of hematoma in rats treated with argatroban and cyclohexmide was 10.7 ± 0.5 mm2 
(n = 9) and 9.9 ± 1.0 mm2 (n = 10), respectively.  These values were not significantly 
different from the value in control rats that received i.c.v. injections of saline (11.9 ± 0.9 mm2, 
n = 8).  Similarly, the size of hematoma in rats treated with PD98059 (11.1 ± 0.9 mm2, n = 7), 
SB203580 (11.8 ± 1.1 mm2, n = 8) or SP600125 (11.0 ± 0.4 mm2, n = 8) was not different 
from that in rats treated with 33% DMSO as vehicle (10.8 ± 0.5 mm2, n = 8). 
ICH is associated with brain edema, which by itself may be deleterious to neuronal viability 
(Hua et al., 2002).  Therefore, we measured brain water content 3 days after collagenase 
injection (Fig. 4).  We observed a robust increase in water content in the tissue containing 
the site of collagenase injection (ipsilateral side of slice A), and to a lesser extent, in the 
adjacent tissue (ipsilateral side of slice B).  Argatroban, cycloheximide, and MAP kinase 
inhibitors had no effect on the increase of brain water content.  Overall, the results indicate 
that the neuroprotective effects of these drugs do not result from suppression of hematoma 
expansion or of edema formation. 
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ERK activation occurs in neurons and microglia after ICH 
Of the MAP kinase inhibitors, PD98059 was most effective in preventing ICH-induced 
neuronal loss.  Accordingly, we examined changes in the activation status of ERK in 
response to ICH.  Western blotting of striatal tissue samples showed that ICH was followed 
by an increase in phosphorylated form of ERK indicating ERK activation.  The increase 
reached a peak at 8 h after collagenase injection and seemed to have a second peak at 48 h 
(Fig. 5A).  The increase in phosphorylated ERK at 8 h after collagenase injection was largely 
suppressed when animals were pretreated with argatroban or PD98059 (Fig. 5B). 
We also performed immunohistochemical staining of phospho-ERK with NeuN or with 
OX-42, a microglial marker, to determine which cell type was responsible for elevated levels 
of phospho-ERK.  Both neurons and microglia within the hematoma area exhibited 
immnoreactivity for phospho-ERK at 8 h after collagenase injection (Fig. 5C-H).  Omission 
of primary antibodies abolished cellular fluorescence staining with secondary antibodies   
(data not shown), thus confirming specificity of immunopositive signals. 
 
MAP kinase inhibitors induce cell death in microglia 
DNA fragmentation as revealed by TUNEL staining occurs in apoptosis and several other 
forms of cell death, and thrombin induces neuronal nuclear fragmentation in vitro and in vivo 
(Donovan et al., 1997; Fujimoto et al., 2007).  Thus, we next performed TUNEL staining to 
verify if the neuroprotective effect of PD98059 was associated with suppression of DNA 
fragmentation.  A substantial number of TUNEL-positive cells appeared in the hematoma 
area at 1 day after collagenase injection.  Unexpectedly, PD98059 applied 1 h before 
collagenase injection did not decrease the number of TUNEL-positive cells (Fig. 6A, B, E and 
F).  Similarly, SB203580 and SP600125 did not inhibit the increase in TUNEL-positive cells 
in response to ICH (Fig. 6C, D, E and F).  Rather, these drugs tended to increase the number 
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of TUNEL-positive cells in the peripheral region of the hematoma (Fig. 6F). 
Then, the types of cells with TUNEL-positive signals were identified by 
immunohistochemisty against specific marker proteins.  In the striatum of animals treated 
with vehicle (33%DMSO), TUNEL-positive cells in the hematoma area at 1 day after 
collagenase injection overlapped with NeuN, a neuronal marker, but not with OX-42, a 
microglial marker (Fig. 7A-F).  On the other hand, a substantial number of TUNEL-positive 
cells showing OX-42 immunoreactivity appeared in the striatum of animals treated with 
PD98059 (Fig. 7G-I).  OX-42-positive cells with TUNEL staining were also observed in 
animals treated with SB203580 and SP600125 (Fig. 7J-O).  These results suggest that 
inhibition of MAP kinases resulted in induction of cell death in microglia.  Therefore, we 
counted the number of OX-42-positive microglia in the hematoma area at 3 days after 
collagenase injection.  At this time point, microglia were almost exclusively localized at the 
peripheral region of hematoma, and few microglia were observed at the hematoma center.  
As shown in Fig. 8, MAP kinase inhibitors tended to decrease the number of microglia in the 
peripheral region, although the difference between vehicle-treated group and drug-treated 
groups did not reach statistical significance. 
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Discussion 
The present study was aimed to reveal whether the same cellular mechanisms as those 
recruited in thrombin-induced neuronal injury were involved in ICH-induced injury in vivo.  
For this purpose, we examined the effects of argatroban, cycloheximide and several MAP 
kinase inhibitors on neuronal injury in collagenase-induced ICH model.  These drugs have 
been shown to block thrombin-induced shrinkage of the striatal tissue in organotypic culture 
(Fujimoto et al., 2006).  Here we demonstrated that ICH-induced decrease in the number of 
surviving neurons in the striatum was significantly prevented by argatroban, cycloheximide 
and MAP kinase inhibitors.  Particularly, neuroprotection by argatroban, a thrombin inhibitor, 
indicates that exaggerated thrombin activity plays an important role in neuronal injury 
associated with ICH.  Moreover, the effectiveness of cyclohexmide, PD98059 and SP600125 
closely parallels the findings in thrombin cytotoxicity on striatal slice culture, and adds further 
support for the idea that signaling pathways triggered by thrombin are involved in the 
pathogenesis of ICH. 
A notable difference between the results of the present study and those of an in vitro study 
was that the protective effects of argatroban and cycloheximide in vivo were only partial, 
whereas these drugs completely blocked striatal shrinkage in slice culture (Fujimoto et al., 
2006).  Similarly, MAP kinase inhibitors showed only a partial neuroprotective effect in the 
present study, although they almost completely blocked striatal tissue injury in vitro.  A 
reasonable explanation for these discrepancies is that ICH-induced neuronal injury may 
involve additional mechanisms independent of thrombin.  For example, blood-derived 
factors other than thrombin, such as hemoglobin and tissue plasminogen activator, may exert 
harmful influences on central neurons (Huang et al., 2002; Wang et al., 2006).  Moreover, 
mass effect of hematoma (Nehls et al., 1990) and the elevation of intracranial pressure can act 
as a cause of brain injury.  Another possible explanation is that thrombin by itself in the in 
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vivo context may also recruit MAP kinase-independent mechanisms leading to neuronal death.  
Indeed, neuronal damage in the striatum induced by direct injection of thrombin was only 
partially prevented by PD98059, SB203580 and SP600125 (Fujimoto et al., 2007).  We also 
cannot entirely exclude the possibility that the drugs at doses tested were not sufficient to 
fully counteract with their targets in the signaling pathways. 
The extent of hematoma expansion and of edema formation was not significantly altered by 
any drugs tested in the present study.  Consistent with our observations, argatroban has been 
reported to show no effect on hematoma size (Kitaoka et al., 2002; Nagatsuna et al., 2005), 
despite the fact that this drug is clinically used for anti-coagulation.  On the other hand, the 
same studies also reported that peripheral administration of argatroban significantly 
suppressed brain edema associated with ICH (Kitaoka et al., 2002; Nagatsuna et al., 2005), 
which is discrepant with our results.  Although we have no obvious explanations for this 
discrepancy, many different conditions in experimental settings might affect the consequences.  
In any case, the results of the present study indicate that neuroprotective effects of drugs 
including argatroban, cycloheximide and MAP kinase inhibitors against ICH-induced injury 
are not secondary to amelioration of physically deleterious factors, i.e., hematoma and edema.  
It should be noted that the types of parameters such as neuron counts, hematoma size and 
brain water content are different in nature, which might be responsible for their different 
sensitivities to drug effects. 
Activation of ERK after ICH, as revealed by an increase in phosphorylated ERK, was 
confirmed by western blot analysis.  The increase in phosphorylated ERK was largely 
abolished by treatment with argatroban, suggesting that thrombin plays a major role in 
activation of ERK following ICH.  Phosphorylation of ERK was observed both in neurons 
and in microglia, which is consistent with the fact that PARs are expressed in both cell types 
(Noobakhsh et al., 2003).  In other words, ERK in both neurons and microglia may have a 
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potential link to neuronal injury in ICH. 
TUNEL staining combined with immunohistochemical identification of cell types indicated 
that the neuroprotective effects of inhibitors of ERK and other MAP kinases may be in part 
mediated by inhibition of microglial activities.  This conclusion was first led by the 
observation that MAP kinase inhibitors did not decrease the number of TUNEL-positive cells 
in the hematoma, while they produced significant neuroprotective effects.  This observation 
was followed by the finding that MAP kinase inhibitors induced TUNEL-positive signals in 
microglia that were not observed in vehicle-treated animals.  Indeed, the number of 
microglia in the hematoma tended to decrease in animals treated with MAP kinase inhibitors, 
suggesting that microglial cell death was induced by these treatments.  Although microglia 
have been reported to exert neuroprotective functions under several circumstances such as 
oxygen-glucose deprivation-induced neuronal damage (Neumann et al., 2006; Schwartz et al., 
2006), we have previously shown that microglial activation plays a crucial role in 
thrombin-induced neuronal injury in the striatum in vitro (Fujimoto et al., 2006).  Moreover, 
partial suppression of microglial activation by a pharmacological treatment significantly 
inhibited thrombin-induced striatal injury in vivo (Fujimoto et al., 2007).  A report by Power 
et al. (2003) has demonstrated that minocycline is neuroprotective against ICH-induced injury 
by suppressing microglial activation and downregulating expression of matrix 
metalloprotease-12.  Therefore, arrestment of the increase in microglia by inhibition of MAP 
kinases may well protect neurons from ICH-induced injury.  In this context, MAP kinase 
signaling pathways have been reported to mediate proliferation of microglia induced by 
corticotropin-releasing hormone (Wang et al., 2003).  On the other hand, many lines of 
evidence have shown that activation of neuronal MAP kinases is deleterious to neurons.  For 
example, ERK activation leads to cell death of rat cerebellar granule neurons through plasma 
membrane damage (Subramaniam et al., 2004).  Relative contribution of neuronal and 
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microglial MAP kinases to ICH-induced neuronal injury should be addressed in detail in 
further investigations. 
In conclusion, we have shown that signaling mechanisms triggered by blood-derived 
thrombin, including MAP kinases, have an important role in ICH-induced neuronal injury.  
We also suggest that one of the roles of activated MAP kinases is to support the survival of 
microglia in the hematomal region, thereby assuring cytotoxic activities of microglia onto 
neurons.  Regulation of MAP kinases and micoglial activities should be an important 
strategy to prevent the progression of pathogenic events associated with ICH.  From a 
clinical point of view, effectiveness of drugs that inhibit thrombin, MAP kinases and 
microglial activities against ICH-induced injury should be investigated in further detail, 
including dosing regimens based solely on post-insult treatments. 
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Figure legends 
Fig. 1  Representative images of NeuN-immunostained coronal sections obtained 3 days 
after sham treatment (saline injection; A and C) or collagenase injection (ICH; B and D).  At 
low magnification (A and B), a decrease in NeuN immunoreactivity was evident at hematoma 
region in ICH group.  Magnified views (C and D) reveal a substantial decrease in the 
number of NeuN-positive cells in the center of hematoma.  Asterisk indicates the peripheral 
region of hematoma. 
 
Fig. 2  Effects of argatroban and cycloheximide on ICH-induced neuronal damage.  (A-D) 
Shown are representative images of NeuN-immunostained coronal sections obtained 3 days 
after intrastriatal injection of saline (Sal; A) or collagenase (Col; B-D).  The animals also 
received intracerebroventricular injections of saline (A and B), argatroban (ARG; C) or 
cycloheximide (CHX; D).  Scale bar = 50 μm.  (E, F) The number of NeuN-positive cells at 
the center (E) and the peripheral region (F) of hematoma.  n = 5-10 for each condition.  *** 
P < 0.001 vs. sham group; # P < 0.05 vs. col + sal group.  Data in panel F were analyzed 
with Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
 
Fig. 3  Involvement of MAP kinases in ICH-induced neuronal damage.  (A-E) 
Representative images of NeuN-immunostained coronal sections obtained 3 days after 
intrastriatal injection of saline (Sal; A) or collagenase (Col; B-E) are shown.  The animals 
also received intracerebroventricular injections of vehicle (33% DMSO; A and B), PD98059 
(PD; C), SB203580 (SB; D) or SP600125 (SP; E).  Scale bar = 50 μm.  (F, G) The number 
of NeuN-positive cells at the center (F) and the peripheral region (G) of hematoma.  n = 5-8 
for each condition.  *** P < 0.001 vs. sham group; # P < 0.05, ## P < 0.01 vs. col + DMSO 
group.  Data in panel F were analyzed with Kruskal-Wallis test followed by Dunn’s multiple 
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comparisons test. 
 
Fig. 4  Brain water content at 3 days after intrastriatal injection of saline (Sal) or collagenase 
(Col).  The upper panel shows the effects of argatroban (ARG) and cycloheximide (CHX), 
and the lower panel shows the effects of PD98059 (PD), SB203580 (SB) and SP600125 (SP).  
These drugs were administered into lateral ventricle.  Slice A includes the site of intrastriatal 
injection, and the adjacent caudal slice was designated as B.  ICH induced a significant 
increase in brain water content, which was not affected by any drugs tested.  n = 4-5 for each 
condition.  ** P < 0.01, *** P < 0.001; N.S., not significant. 
 
Fig. 5  Activation of ERK in response to ICH.  (A) Phosphorylation of ERK at indicated 
time points after intrastriatal injection of saline or collagenase.  (B) Effects of argatroban 
(ARG) and PD98059 (PD) on ERK phosphorylation were determined at 8 h after intrastriatal 
injection of saline or collagenase.  Saline (Sal), ARG and PD were administered into lateral 
ventricle 1 h before intrastriatal injection of saline or collagenase.  Panels A and B are 
representative images, each from 5 independent sets of experiments.  (C-H) 
Immunohistochemistry of phosphorylated ERK (p-ERK) with NeuN (C-E) or with OX-42 
(F-H) on sections obtained at 8 h after collagenase injection.  Arrows in merged images (E 
and H) indicate co-localization of immunopositive signals.  Scale bar = 20 μm. 
 
Fig. 6  Effects of MAP kinase inhibitors on the number of TUNEL-positive cells appearing 
after ICH.  (A-D) Representative TUNEL images of the peripheral region of hematoma in 
coronal sections obtained 1 day after intrastriatal injection of collagenase.  The animals also 
received intracerebroventricular injections of vehicle (33% DMSO; A), PD98059 (PD; B), 
SB203580 (SB; C) or SP600125 (SP; D).  Scale bar = 50 μm.  (E, F) The number of 
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TUNEL-positive cells at the center (E) and the peripheral region (F) of hematoma at 1 day 
after collagenase injection.  n = 6-7 for each condition. 
 
Fig. 7  Identification of TUNEL-positive cells.  TUNEL with immunohistochemistry was 
done on brain sections obtained 1 day after collagenase injection.  Animals also received 
intracerebroventricular injection of vehicle (DMSO), PD98059 (PD), SB203580 (SB) or 
SP600125 (SP) 1 h before collagenase injection.  In vehicle-treated animals, TUNEL 
staining colocalized with NeuN immunoreactivity (A-C) but not with OX-42 
immunoreactivity (D-F).  In contrast, substantial colocalization of TUNEL staining with 
OX-42 immunoreactivity, indicated by arrows, was observed in animals treated with PD (G-I), 
SB (J-L) and SP (M-O).  Scale bar = 20 μm. 
 
Fig. 8  Effects of MAP kinase inhibitors on the number of microglia in the peripheral region 
of hematoma.  (A-D) OX-42 immunohistochemistry was done on brain sections obtained 3 
days after collagenase injection.  Animals also received intracerebroventricular injection of 
vehicle (DMSO; A), PD98059 (PD; B), SB203580 (SB; C) or SP600125 (SP; D).  Scale bar 
= 50 μm.  (E) The number of microglia in the peripheral region of hematoma at 3 days after 
collagenase injection.  n = 7-8 for each condition. 
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